EcPLA
Chemical compound
From Wikipedia, the free encyclopedia
EcPLA, also known as N-ethyl-N-cyclopropyllysergamide or as lysergic acid ethylcyclopropylamide (LAEcP), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[2][3][4] It is an isomer of LSZ and is closely related to other amide-substituted lysergamides like MiPLA.[3][2][5][4] The drug has been encountered as a novel designer drug.[4]
- DE: NpSG (Industrial and scientific use only)
- UK: Under Psychoactive Substances Act
- Illegal in France[1]
 | |
 | |
| Clinical data | |
|---|---|
| Other names | ECYPLA; N-Ethyl-N-cyclopropyllysergamide; Lysergic acid ethylcyclopropylamide; LAEcP |
| Routes of administration | Oral |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C21H25N3O |
| Molar mass | 335.451 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Use and effects
EcPLA produces psychedelic effects in humans.[4]
Interactions
Pharmacology
Pharmacodynamics
EcPLA has been found to interact with serotonin receptors and dopamine receptors, among other targets. It is a high potency agonist of the serotonin receptors, with its highest binding affinities at the 5-HT1A (Ki = 3.2 nM), 5-HT2B (Ki = 5.3 nM), and 5-HT5A (Ki = 8.6 nM) subtypes. Its 5-HT2A affinity is equivalent to that of LSD, while the affinity to 5-HT2C receptors is 3 times lower than LSD. It shares much of its binding profile with LSD, but does not bind to β1 or β2 adrenergic receptors as LSD does.[3]
The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It has about 40% of the potency of LSD in this regard.[3]
Pharmacokinetics
The in-vitro metabolism of EcPLA has been studied.[6]
Chemistry
History
EcPLA was first described in the scientific literature by a team that included Adam Halberstadt, Alexander Stratford, Jason Wallach, and David E. Nichols in 2019.[3] It was developed by Lizard Labs.[citation needed] The drug was encountered online as a novel designer drug in around 2020 and became more widely available in early 2022.[4]